ArticleCancer discovery2022
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.
5 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 309 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
309citing papers in PubMed, 4 pooled it
22.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I Study of Low Dose Radiotherapy and Concurrent SBRT in Combination With PD-1 Inhibitors in Advanced Non-small Cell Lung Cancer (NSCLC) .
First-line Anti-PD-1 Therapy Plus Chemotherapy With or Without Radiotherapy in Metastatic Esophageal Squamous Cell Carcinoma: A Phase II Multi-center Trial (SCR-ESCC-01)
Efficacy and Safety of Low-dose Radiation Combined With Neoadjuvant Chemotherapy and Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma
The Combination of AK104 and Low-dose Radiation Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma After Failure of First-line Systemic Therapy: a Phase II Study
Low-dose Radiotherapy (LDRT) Combined With Toripalimab and GP Chemotherapy for Recurrent/Metastatic Nasopharyngeal Carcinoma (LIGHT): A Multicentre, Open-Label, Single-Arm Phase II Clinical Study
Who cites it
309 citing papers in PubMed, 4 syntheses or guidelines pooled it, 396 citations in OpenAlex.
- Efficacy and safety of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced esophagogastric junction or gastric cancer: a systematic review and meta analysis.Frontiers in immunology · 2026Pooled it
- Progress in immunotherapy for resectable head and neck squamous cell carcinoma.Medical oncology (Northwood, London, England) · 2025Pooled it
- Synergies between radiotherapy and immunotherapy: a systematic review from mechanism to clinical application.Frontiers in immunology · 2025Pooled it
- Immune modulatory roles of radioimmunotherapy: biological principles and clinical prospects.Frontiers in immunology · 2024Pooled it
- Circulating immune cell profiling in advanced cervical and endometrial cancer patients treated with PD-1 blockade, radiotherapy, and immune modulation in the PRIMMO trial.Frontiers in immunology · 2026Trial
- Sintilimab plus fruquintinib with or without radiotherapy for third-line treatment of colorectal cancer with liver metastases: study protocol for a randomized controlled, multicenter phase II trial.Frontiers in immunology · 2026Trial
- Whole-body CD8Nature communications · 2025Trial
- Consolidative stereotactic radiotherapy for oligo-residual non-small cell lung cancer after first-line chemoimmunotherapy: A single-arm, phase 2 trial from China.PLoS medicine · 2025Trial
- Neoadjuvant with low-dose radiotherapy, tislelizumab, albumin-bound paclitaxel, and cisplatin for resectable locally advanced head and neck squamous cell carcinoma: phase II single-arm trial.Nature communications · 2025Trial
- A phase II randomized trial of individualized neoantigen peptide vaccine combined with unusual radiotherapy (iNATURE) in advanced solid tumors-GCOG0028.Frontiers in immunology · 2025Trial
- Unlocking the therapeutic potential of immuno-radiotherapy: insights from preclinical and clinical research.Oncoimmunology · 2026Review
- Heterogeneous Radioimmunotherapy for Bulky Tumors: A Phase 1 Trial for Advanced Non-Small Cell Lung Cancer.Advances in radiation oncology · 2026Article
- Tumor-Regional Immune Microenvironment: A Critical Factor in the Design of Radiotherapy-Immunotherapy Combination Trials.International journal of cancer · 2026Review
- Low-dose radiotherapy as an immunomodulator in cancer: dose-specific mechanisms and hybrid high-dose/low-dose strategies.Biomarker research · 2026Review
- Evidence-steered medicine in oncology: network-aware micro-combinations that safeguard standard of care and potentially improve benefit-risk.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Ursodeoxycholic acid enhances cancer radioimmunotherapy by releasing a human-biased FXR-TRIM22-STAT1 immune brake.Cell research · 2026Article
- Tumor cell membrane‑coated MOF‑199 nanoparticles co‑loaded with auranofin and celecoxib enhance single‑dose radiotherapy and anti‑PD‑L1 therapy in cervical cancer.Journal of nanobiotechnology · 2026Article
- Challenges and opportunities in combining radiotherapy and immunotherapy for localized pancreatic cancer.Nature reviews. Gastroenterology & hepatology · 2026Review
- Clinical evaluation of low-dose radiation therapy for immunotherapy resistance in advanced non-small cell lung cancer.Translational cancer research · 2026Article
- Combining Radiation Therapy and Tumor-Infiltrating Lymphocyte Therapy: Biological Rationale, Clinical Synergies, and Future Directions.Current oncology (Toronto, Ont.) · 2026Review
249 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors at 6 institutions in 3 countries.
Fernanda G HerreraLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0001-7984-0472
Catherine RonetLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0003-1479-2873
Maria Ochoa de Olza *Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-2445-6892
David Barras *Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.
Isaac Crespo *Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.
Massimo AndreattaLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-8036-2647
Jesus Corria-OsorioLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.
Aodrenn SpillLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.
Fabrizio BenedettiLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-9959-9142
Raphael GenoletLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.
Angela OrcurtoImmuno-oncology Service, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
Martina ImbimboImmuno-oncology Service, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.ORCID 0000-0003-2521-7540
Eleonora GhisoniImmuno-oncology Service, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
Blanca Navarro RodrigoImmuno-oncology Service, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
Dominik R BertholdMedical Oncology Service, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.ORCID 0000-0002-1552-6617
Apostolos SarivalasisMedical Oncology Service, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
Khalil ZamanMedical Oncology Service, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
Rafael DuranDepartment of Radiology and Interventional Radiology, Lausanne University Hospital, Lausanne, Switzerland.
Clarisse DromainDepartment of Radiology and Interventional Radiology, Lausanne University Hospital, Lausanne, Switzerland.ORCID 0000-0002-2999-1958
John PriorDepartment of Nuclear Medicine, Lausanne University Hospital, Lausanne, Switzerland.ORCID 0000-0003-1429-1374
Niklaus SchaeferDepartment of Nuclear Medicine, Lausanne University Hospital, Lausanne, Switzerland.
Jean BourhisRadiation Oncology Service, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
Georgia DimopoulouUnit of Translational Oncopathology, Institute of Pathology, Lausanne University Hospital, Lausanne, Switzerland.
Zoi TsourtiUnit of Translational Oncopathology, Institute of Pathology, Lausanne University Hospital, Lausanne, Switzerland.
Marius MessemakerCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-7179-0594
Thomas SmithNanoString Technologies Inc., Seattle, Washington.
Sarah E WarrenNanoString Technologies Inc., Seattle, Washington.
Periklis FoukasSecond Department of Pathology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Sylvie RusakiewiczSchool of Nursing, National and Kapodistrian University of Athens, Athens, Greece.ORCID 0000-0001-5939-5690
Mikaël J PittetCenter for Systems Biology, Massachusetts General Hospital Research Institute and Harvard Medical School, Boston, Massachusetts.
Stefan ZimmermannImmuno-oncology Service, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
Christine SempouxUnit of Translational Oncopathology, Institute of Pathology, Lausanne University Hospital, Lausanne, Switzerland.ORCID 0000-0003-1375-3979
Urania DafniSchool of Nursing, National and Kapodistrian University of Athens, Athens, Greece.ORCID 0000-0003-4367-4497
Alexandre HarariLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.
Lana E KandalaftLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-1575-6674
Santiago J CarmonaLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-2495-0671
Denarda Dangaj LanitiLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-5659-6427
Melita Irving *Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-6849-7194
George Coukos *Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland. George.Coukos@chuv.ch.
Ludwig Cancer Research · CHUniversity of Lausanne · CHNational and Kapodistrian University of Athens · GRNanostring Technologies (United States) · USCenter for Systems Biology · USUniversity of Geneva · CH
Funding
No grant is acknowledged in the PubMed record.
Abstract
Developing strategies to inflame tumors is critical for increasing response to immunotherapy. Here, we report that low-dose radiotherapy (LDRT) of murine tumors promotes T-cell infiltration and enables responsiveness to combinatorial immunotherapy in an IFN-dependent manner. Treatment efficacy relied upon mobilizing both adaptive and innate immunity and depended on both cytotoxic CD4
Indexed as
Adaptive ImmunityAdenocarcinoma, PapillaryAnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesDisease Models, AnimalFemaleHumansLymphocytes, Tumor-InfiltratingMiceMice, Inbred C57BLOvarian NeoplasmsRadiotherapy DosageTumor Microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT05615142ClinicalTrials.gov
NCT05978193ClinicalTrials.gov
NCT06446726ClinicalTrials.gov
NCT06494995ClinicalTrials.gov
NCT07325539ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.